Should I buy or sell Zynex stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZYXI shares. View ZYXI analyst ratings or view top-rated stocks .

What is Zynex's stock price target for 2024?

2 Wall Street analysts have issued 1 year target prices for Zynex's stock. Their ZYXI share price targets range from $15.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 50.5% from the stock's current price. View analysts price targets for ZYXI or view top-rated stocks among Wall Street analysts .

How have ZYXI shares performed in 2024?

Zynex's stock was trading at $10.89 at the beginning of the year. Since then, ZYXI stock has increased by 9.8% and is now trading at $11.96. View the best growth stocks for 2024 here .

When is Zynex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our ZYXI earnings forecast .

How were Zynex's earnings last quarter?

Zynex, Inc. (NASDAQ:ZYXI) posted its earnings results on Thursday, February, 29th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.17 by $0.13. The firm earned $47.28 million during the quarter, compared to analysts' expectations of $54.53 million. Zynex had a net margin of 5.28% and a trailing twelve-month return on equity of 16.82%. The business's revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.20 earnings per share.

What guidance has Zynex issued on next quarter's earnings?

Zynex issued an update on its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of 0.030- for the period, compared to the consensus estimate of 0.040. The company issued revenue guidance of $47.5 million-, compared to the consensus revenue estimate of $47.7 million.

What is Thomas Sandgaard's approval rating as Zynex's CEO?

81 employees have rated Zynex Chief Executive Officer Thomas Sandgaard on Glassdoor.com . Thomas Sandgaard has an approval rating of 87% among the company's employees.

Who are Zynex's major shareholders?

Zynex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bridge City Capital LLC (0.58%) and Congress Asset Management Co. MA (0.37%). Insiders that own company stock include Anna Lucsok, Daniel J Moorhead and Thomas Sandgaard . View institutional ownership trends .

How do I buy shares of Zynex?

Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:ZYXI

Zynex (ZYXI) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free ZYXI Stock Alerts

$11.96

+0.05 (+0.42%)

(As of 04/15/2024 ET)

Compare

Today's Range: $11.80
▼
$12.10
50-Day Range: $11.91
▼
$13.74
52-Week Range: $6.88
▼
$14.75

Volume: 91,199 shs
Average Volume: 246,889 shs
Market Capitalization: $384.75 million

P/E Ratio: 44.30
Dividend Yield: N/A
Price Target: $18.00

Get Zynex alerts:

Zynex MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 50.5% Upside
$18.00 Price Target
Short Interest: Bearish
31.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 91.84%
From $0.49 to $0.94 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

309th out of 929 stocks

Electromedical Equipment Industry

5th out of 18 stocks

3.5

Analyst's Opinion

Consensus Rating
Zynex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Zynex has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
31.73% of the float of Zynex has been sold short.
Short Interest Ratio / Days to Cover
Zynex has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Zynex has recently decreased by 1.37%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Zynex does not currently pay a dividend.
Dividend Growth
Zynex does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZYXI.

2.7

News and Social Media Coverage

News Sentiment
Zynex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Zynex this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for ZYXI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Zynex to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zynex insiders have not sold or bought any company stock.
Percentage Held by Insiders
52.13% of the stock of Zynex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 29.68% of the stock of Zynex is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Zynex are expected to grow by 91.84% in the coming year, from $0.49 to $0.94 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zynex is 44.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.21.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zynex is 44.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 248.92.
Price to Book Value per Share Ratio
Zynex has a P/B Ratio of 8.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Zynex Stock (NASDAQ:ZYXI)

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

ZYXI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZYXI Stock News Headlines

April 2, 2024 | investorplace.com

3 Industrial Stocks Short Sellers Are Hammering: Cracks in the Foundation?

April 2, 2024 | prnewswire.com

Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

March 30, 2024 | finance.yahoo.com

With 51% ownership, Zynex, Inc. (NASDAQ:ZYXI) insiders have a lot riding on the company's future

March 16, 2024 | finance.yahoo.com

ZYXI Aug 2024 20.000 call

March 15, 2024 | wsj.com

Zynex Inc.

March 3, 2024 | finance.yahoo.com

Zynex Full Year 2023 Earnings: Misses Expectations

March 2, 2024 | seekingalpha.com

Zynex, Inc. (ZYXI) Q4 2023 Earnings Call Transcript

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

March 2, 2024 | finance.yahoo.com

Zynex, Inc. (NASDAQ:ZYXI) Q4 2023 Earnings Call Transcript

March 1, 2024 | markets.businessinsider.com

Here's what to expect from Zynex's earnings

March 1, 2024 | finance.yahoo.com

Zynex Price Target Raised by RBC Capital, HC Wainwright Analysts

February 29, 2024 | benzinga.com

Zynex: Q4 Earnings Insights

February 29, 2024 | msn.com

Zynex GAAP EPS of $0.04 misses by $0.13, revenue of $47.28M misses by $8.34M

February 29, 2024 | finance.yahoo.com

Zynex Inc (ZYXI) Reports 17% Revenue Growth in FY 2023, Announces New $20 Million Stock ...

February 29, 2024 | finance.yahoo.com

Zynex Reports Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024 | prnewswire.com

Zynex Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024 | benzinga.com

Earnings Preview: Zynex

February 22, 2024 | finance.yahoo.com

Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call

February 22, 2024 | prnewswire.com

Zynex Sets Fourth Quarter and Full Year 2023 Earnings Call

February 20, 2024 | finance.yahoo.com

Zynex Introduces New Products

February 20, 2024 | prnewswire.com

Zynex Introduces New Products

February 6, 2024 | msn.com

Zynex gets FDA clearance for M-Wave muscle stimulation device

February 6, 2024 | markets.businessinsider.com

Zynex Says FDA Clears M-Wave Neuromuscular Electrical Stimulation Device

February 6, 2024 | finance.yahoo.com

Zynex Receives FDA Clearance for its Next Generation NMES Device

February 2, 2024 | finance.yahoo.com

Zynex Recognized in Top 25 Medical Device Companies for 2024

January 28, 2024 | markets.businessinsider.com

3 Unloved Growth Stocks Poised for a Major Turnaround

See More Headlines

Receive ZYXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/15/2024
Next Earnings (Estimated): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:ZYXI
CUSIP: N/A
CIK: 846475
Web: www.zynex.com
Phone: (303) 703-4906
Fax: N/A
Employees: 1,100
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.00
High Stock Price Target: $21.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +50.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.27
Trailing P/E Ratio: 44.30
Forward P/E Ratio: 24.41
P/E Growth: N/A
Net Income: $9.73 million
Net Margins: 5.28%
Pretax Margin: 6.82%
Return on Equity: 16.82%
Return on Assets: 7.05%

Debt

Debt-to-Equity Ratio: 1.26
Current Ratio: 4.74
Quick Ratio: 4.03

Sales & Book Value

Annual Sales: $184.32 million
Price / Sales: 2.09
Cash Flow: $0.41 per share
Price / Cash Flow: 28.94
Book Value: $1.36 per share
Price / Book: 8.79

Miscellaneous

Outstanding Shares: 32,170,000
Free Float: 15,400,000
Market Cap: $384.75 million
Optionable: Optionable
Beta: 0.48

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Thomas Sandgaard (Age 65)
Founder, President, CEO & Chairman
Comp: $1.14M
Mr. Daniel J. Moorhead (Age 52)
Chief Financial Officer
Comp: $423.77k
Ms. Anna Lucsok (Age 37)
Chief Operating Officer
Comp: $356.25k
Mr. Steve Fox
Vice President Of Sales
Mr. Donald Gregg
President of Zynex Monitoring Solutions
Mr. Neil Friery
President & COO of Zynex Monitoring Solutions, Inc.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZYXI Stock Analysis - Frequently Asked Questions

Should I buy or sell Zynex stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZYXI shares.
View ZYXI analyst ratings or view top-rated stocks.
What is Zynex's stock price target for 2024?: 2 Wall Street analysts have issued 1 year target prices for Zynex's stock. Their ZYXI share price targets range from $15.00 to $21.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 50.5% from the stock's current price.
View analysts price targets for ZYXI or view top-rated stocks among Wall Street analysts.
How have ZYXI shares performed in 2024?: Zynex's stock was trading at $10.89 at the beginning of the year. Since then, ZYXI stock has increased by 9.8% and is now trading at $11.96.
View the best growth stocks for 2024 here.
When is Zynex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ZYXI earnings forecast.
How were Zynex's earnings last quarter?: Zynex, Inc. (NASDAQ:ZYXI) posted its earnings results on Thursday, February, 29th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.17 by $0.13. The firm earned $47.28 million during the quarter, compared to analysts' expectations of $54.53 million. Zynex had a net margin of 5.28% and a trailing twelve-month return on equity of 16.82%. The business's revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.20 earnings per share.

What guidance has Zynex issued on next quarter's earnings?: Zynex issued an update on its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of 0.030- for the period, compared to the consensus estimate of 0.040. The company issued revenue guidance of $47.5 million-, compared to the consensus revenue estimate of $47.7 million.
What is Thomas Sandgaard's approval rating as Zynex's CEO?: 81 employees have rated Zynex Chief Executive Officer Thomas Sandgaard on Glassdoor.com. Thomas Sandgaard has an approval rating of 87% among the company's employees.
Who are Zynex's major shareholders?: Zynex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bridge City Capital LLC (0.58%) and Congress Asset Management Co. MA (0.37%). Insiders that own company stock include Anna Lucsok, Daniel J Moorhead and Thomas Sandgaard.
View institutional ownership trends.
How do I buy shares of Zynex?: Shares of ZYXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZYXI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial